Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis

Abstract Introduction Long‐acting injectable cabotegravir (CAB‐LA) demonstrated superiority to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP) in two clinical trials. This analysis projects the impact of expanding PrE...

Full description

Bibliographic Details

Published in:	Journal of the International AIDS Society
Main Authors:	Sarah E. Stansfield, Mia Moore, Lise Jamieson, Gesine Meyer‐Rath, Leigh F. Johnson, David Kaftan, Anna Bershteyn, Jennifer Smith, Valentina Cambiano, Loveleen Bansi‐Matharu, Andrew Phillips, Jesse Heitner, Ruanne V. Barnabas, Brett Hanscom, Deborah J. Donnell, Marie‐Claude Boily, Dobromir Dimitrov
Format:	Article
Language:	English
Published:	Wiley 2025-07-01
Subjects:	adherence CAB‐LA HIV prevention modelling pre‐exposure prophylaxis South Africa
Online Access:	https://doi.org/10.1002/jia2.26453